InMed Pharmaceuticals Inc. (TSE:IN – Get Rating) was down 1.6% on Monday . The company traded as low as C$4.13 and last traded at C$4.19. Approximately 17,035 shares were traded during trading, a decline of 42% from the average daily volume of 29,552 shares. The stock had previously closed at C$4.26.
InMed Pharmaceuticals Stock Performance
The firm’s 50 day moving average price is C$4.19. The company has a market cap of C$33.73 million and a price-to-earnings ratio of -2.77. The company has a current ratio of 2.13, a quick ratio of 1.45 and a debt-to-equity ratio of 8.48.
About InMed Pharmaceuticals
InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain.
Featured Stories
- Does it Matter Folks Aren’t “Starry-Eyed” Over Pepsi’s New Soda?
- Can Alaska Air Continue Soaring Above The Airline Industry?
- Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
- Insulet Has Potential To Gain More Than Analysts Are Forecasting
- Cathie Wood Is Buying These Stocks, Should You?
Receive News & Ratings for InMed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
